Funds advised by Apax Partners recently announced an agreement to sell their controlling stake in Neuraxpharm – a leading European specialty pharmaceutical firm focused on the treatment of central nervous system disorder (CNS) – to funds advised by Permira.

Neuraxpharm focuses on improving the mental well-being and the quality of life of patients affected by CNS disorders throughout the European region. Its operations are active in 13 countries and cover 80% of the European CNS drug market.

Back in 2016, Apax Funds saw the opportunity to generate an European leader in CNS specialty pharmaceuticals.Following these lines, the PE investment group acquired Invent Farma in Spain and neuraxpharma Arzneimittel in Germany, leading to the foundations of the Neuraxpharm group.

• Neuraxpharm today has annual revenues in excess of €460 million and 850 employees.

Source: Apax

‍